SPONSOR
Beijing Hospital
Total Trials
3
Recruiting
3
Phases
Phase 2
Conditions studied: RAS MutationMetastatic Colorectal CancerMSSType 2 Diabetic PatientsT2DM (Type 2 Diabetes Mellitus)T2DMMoyamoya DiseaseIntracranial HemorrhagesStroke
Beijing Hospital is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including RAS Mutation, Metastatic Colorectal Cancer, MSS, Type 2 Diabetic Patients.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Beijing Hospital
How many clinical trials has Beijing Hospital sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Beijing Hospital, of which 3 are actively recruiting participants. These trials cover conditions including RAS Mutation, Metastatic Colorectal Cancer, MSS. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Beijing Hospital research focus on?
Beijing Hospital clinical trials span RAS Mutation, Metastatic Colorectal Cancer, MSS, Type 2 Diabetic Patients, T2DM (Type 2 Diabetes Mellitus), and additional conditions. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Beijing Hospital clinical trial?
To participate in a Beijing Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Beijing Hospital trials with current recruitment status updated daily.
Clinical Trials by Beijing Hospital
NCT06321081 Phase 2
Recruiting
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
RAS Mutation
NCT03987308
Recruiting
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
Type 2 Diabetic Patients
NCT07781579
Recruiting
5T MRI and Metabolomics-Based Hemorrhage Risk Prediction in Moyamoya Disease
Moyamoya Disease
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology